Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Orimeten 250mg tablets
0803041A0BBAAAA
|
Orimeten | Aminoglutethimide | Malignant Disease and Immunosuppression | No data available |
|
Orkambi 100mg/125mg granules sachets
0307000T0BBACAC
|
Orkambi | Lumacaftor/ivacaftor | Respiratory System | No data available |
|
Orkambi 100mg/125mg tablets
0307000T0BBABAB
|
Orkambi | Lumacaftor/ivacaftor | Respiratory System | No data available |
|
Orkambi 150mg/188mg granules sachets
0307000T0BBADAD
|
Orkambi | Lumacaftor/ivacaftor | Respiratory System | No data available |
|
Orkambi 200mg/125mg tablets
0307000T0BBAAAA
|
Orkambi | Lumacaftor/ivacaftor | Respiratory System | No data available |
|
Orlept 200mg gastro-resistant tablets
0408010W0BEAAAC
|
Orlept | Sodium valproate | Central Nervous System | No data available |
|
Orlistat 27mg chewable tablets
0405010P0AAACAC
|
Orlistat | Orlistat | Central Nervous System | No data available |
|
Ornithine powder
0913445A0AAAFAF
|
Pdr disc/non ACBS single L-amino acid supplement (0913445) | Pdr disc/non ACBS single L-amino acid supplement (0913445) | Nutrition and Blood | No data available |
|
Oromag 160 tablets
0101010I0BEABAL
|
Oromag 160 | Magnesium oxide | Gastro-Intestinal System | No data available |
|
Orovite High Potency B & C Vitamins tablets
090607000BBCJBB
|
Proprietary compound preparation BNF 0906070 | Other multivitamin preparations | Nutrition and Blood | No data available |
|
Orphacol 250mg capsules
0109010H0BBABAE
|
Orphacol | Cholic acid | Gastro-Intestinal System | No data available |
|
Orphacol 50mg capsules
0109010H0BBAAAI
|
Orphacol | Cholic acid | Gastro-Intestinal System | No data available |
|
Orphenadrine 25mg/5ml oral solution
0409020N0AAAKAK
|
Orphenadrine hydrochloride | Orphenadrine hydrochloride | Central Nervous System | No data available |
|
Orphenadrine 25mg/5ml oral solution sugar free
0409020N0AAABAB
|
Orphenadrine hydrochloride | Orphenadrine hydrochloride | Central Nervous System | No data available |
|
Ortho All-Flex arcing spring silicone diaphragm
21040000442
|
Ortho All-Flex arcing spring silicone diaphragm | Contraceptive Devices | Appliances | No data available |
|
Ortho-Creme 2% contraceptive cream
0703030G0BFAAAB
|
Ortho-Creme | Nonoxinol 9 | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Ortho-Gynest 500microgram pessaries
0702010F0BBAAAB
|
Ortho-Gynest | Estriol | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Orthoforms 5% contraceptive pessaries
0703030G0BGAAAH
|
Ortho-Forms | Nonoxinol 9 | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Orthovisc 30mg/2ml injection pre-filled syringes
21012000116
|
Orthovisc 30mg/2ml injection pre-filled syringes | Other Appliances | Appliances | No data available |
|
Orthovisc mini 15mg/1ml injection pre-filled syringes
21012000117
|
Orthovisc mini 15mg/1ml injection pre-filled syringes | Other Appliances | Appliances | No data available |
|
Orudis 100mg capsules
1001010L0BCABAB
|
Orudis | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Orudis 100mg suppositories
1001010L0BCACAP
|
Orudis | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Orudis 50mg capsules
1001010L0BCAAAA
|
Orudis | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Oruvail 150 modified-release capsules
1001010L0BDADAL
|
Oruvail (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Oruvail IM 100mg/2ml solution for injection ampoules
1001010L0BDACAG
|
Oruvail (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.